Italia markets close in 4 hours 23 minutes

FTSE MIB
34.772,69
+280,28(+0,81%)
Dow Jones
38.686,32
+574,82(+1,51%)
Nasdaq
16.735,02
-2,08(-0,01%)
Nikkei 225
38.923,03
+435,13(+1,13%)
Petrolio
76,98
-0,01(-0,01%)
Bitcoin EUR
63.556,54
+1.324,62(+2,13%)

NVCR Dec 2025 90.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,2000

0,0000

(0,00%)

In data: 02:32PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in